PMID- 15221995
OWN - NLM
STAT- MEDLINE
DCOM- 20040716
LR  - 20151119
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 101
IP  - 1
DP  - 2004 Jul 1
TI  - Association between serum levels of soluble tumor necrosis factor receptors/CA 
      125 and disease progression in patients with epithelial ovarian malignancy: a 
      gynecologic oncology group study.
PG  - 106-15
AB  - BACKGROUND: A prospective study was undertaken within the Gynecologic Oncology 
      Group to determine whether serum levels of soluble tumor necrosis factor 
      receptors I (sTNFR-I) and II (sTNFR-II), alone or in combination with CA 125, 
      were associated with clinicopathologic characteristics or outcome in patients 
      with epithelial ovarian malignancies. METHODS: Quantitative immunoassays were 
      performed on valid pretreatment serum specimens obtained from patients with 
      epithelial ovarian malignancies to assess levels of sTNFR-I, sTNFR-II, and CA 
      125. The authors then analyzed the results of these immunoassays for potential 
      correlations with clinicopathologic characteristics and outcome. RESULTS: The 
      median age of the 139 women evaluated was 59 years. Seventy-eight percent had 
      Stage III or IV disease, and 58% had serous carcinomas. sTNFR-II was associated 
      with age (P = 0.013), and CA 125 was associated with histologic subtype (P = 
      0.0009). In addition, sTNFR-I (P = 0.037) and CA 125 (P < 0.0001) were associated 
      with extent of disease. After adjusting for patient age, histologic subtype, and 
      extent of disease, all three biomarkers were predictive of progression-free 
      survival, but not overall survival, when the combination was included in the 
      model. The authors observed a 51% reduction (hazard ratio [HR], 0.49; 95% 
      confidence interval [CI], 0.24-0.99), a 2.9-fold increase (HR, 2.87; 95% CI, 
      1.15-7.20), and a 22% increase (HR, 1.22; 95% CI, 0.99-1.51) in the risk of 
      progression for each unit increase in the log-transformed levels of sTNFR-I, 
      sTNFR-II, and CA 125, respectively. CONCLUSIONS: The observations made in the 
      current study-that among patients with low or high CA 125 levels, those with high 
      sTNFR-I levels and low sTNFR-II levels had the lowest risk, that patients with 
      low-low or high-high sTNFR-I and sTNFR-II levels, respectively, had an 
      intermediate risk, and that patients with low sTNFR-I levels and high sTNFR-II 
      levels had the highest risk of progression-suggested the potential value of 
      simultaneous assessment of all three biomarkers in patients with epithelial 
      ovarian malignancies.
CI  - Copyright 2004 American Cancer Society.
FAU - Burger, Robert A
AU  - Burger RA
AD  - Department of Obstetrics and Gynecology, University of California-Irvine Medical 
      Center, Orange, CA, USA.
FAU - Darcy, Kathleen M
AU  - Darcy KM
FAU - DiSaia, Philip J
AU  - DiSaia PJ
FAU - Monk, Bradley J
AU  - Monk BJ
FAU - Grosen, Elizabeth A
AU  - Grosen EA
FAU - Gatanaga, Tetsuya
AU  - Gatanaga T
FAU - Granger, Gale A
AU  - Granger GA
FAU - Wang, Jianmin
AU  - Wang J
FAU - Tian, Chunqiao
AU  - Tian C
FAU - Hanjani, Parviz
AU  - Hanjani P
FAU - Cohn, David E
AU  - Cohn DE
LA  - eng
GR  - CA 27469/CA/NCI NIH HHS/United States
GR  - CA 37517/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/blood
MH  - CA-125 Antigen/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Etanercept
MH  - Female
MH  - History, 16th Century
MH  - Humans
MH  - Immunoglobulin G/*blood
MH  - Middle Aged
MH  - Neoplasms, Glandular and Epithelial/*blood/mortality/pathology
MH  - Ovarian Neoplasms/*blood/mortality/pathology
MH  - Receptors, Tumor Necrosis Factor/*blood
EDAT- 2004/06/29 05:00
MHDA- 2004/07/17 05:00
CRDT- 2004/06/29 05:00
PHST- 2004/06/29 05:00 [pubmed]
PHST- 2004/07/17 05:00 [medline]
PHST- 2004/06/29 05:00 [entrez]
AID - 10.1002/cncr.20314 [doi]
PST - ppublish
SO  - Cancer. 2004 Jul 1;101(1):106-15. doi: 10.1002/cncr.20314.